Aaron G.L. Fletcher - Aug 3, 2021 Form 4 Insider Report for IN8BIO, INC. (INAB)

Role
10%+ Owner
Signature
/s/ Aaron Glenn Louis Fletcher
Stock symbol
INAB
Transactions as of
Aug 3, 2021
Transactions value $
$0
Form type
4
Date filed
8/3/2021, 04:53 PM
Previous filing
Jul 29, 2021
Next filing
Aug 17, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction INAB Common Stock Conversion of derivative security +574K 574K Aug 3, 2021 See footnote F1, F2, F3, F4, F5, F6
transaction INAB Common Stock Conversion of derivative security +1.88M 1.88M Aug 3, 2021 See footnote F1, F3, F4, F5, F6, F7
transaction INAB Common Stock Conversion of derivative security +251K 251K Aug 3, 2021 See footnote F1, F3, F4, F5, F6, F8
transaction INAB Common Stock Conversion of derivative security +997K 997K Aug 3, 2021 See footnote F1, F3, F4, F5, F6, F9
transaction INAB Common Stock Conversion of derivative security +341K 341K Aug 3, 2021 See footnote F1, F3, F4, F5, F6, F10
transaction INAB Common Stock Conversion of derivative security +2.23M 2.23M Aug 3, 2021 See footnote F1, F3, F4, F5, F6, F11
transaction INAB Common Stock Conversion of derivative security +359K 359K Aug 3, 2021 See footnote F1, F3, F4, F5, F6, F12

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction INAB Series A Preferred Stock Conversion of derivative security $0 -522K -100% $0.00* 0 Aug 3, 2021 Common Stock 574K See footnote F1, F2, F3, F4, F5, F6
transaction INAB Series A Preferred Stock Conversion of derivative security $0 -1.71M -100% $0.00* 0 Aug 3, 2021 Common Stock 1.88M See footnote F1, F3, F4, F5, F6, F7
transaction INAB Series A Preferred Stock Conversion of derivative security $0 -228K -100% $0.00* 0 Aug 3, 2021 Common Stock 251K See footnote F1, F3, F4, F5, F6, F8
transaction INAB Series A Preferred Stock Conversion of derivative security $0 -907K -100% $0.00* 0 Aug 3, 2021 Common Stock 997K See footnote F1, F3, F4, F5, F6, F9
transaction INAB Series A Preferred Stock Conversion of derivative security $0 -310K -100% $0.00* 0 Aug 3, 2021 Common Stock 341K See footnote F1, F3, F4, F5, F6, F10
transaction INAB Series A Preferred Stock Conversion of derivative security $0 -2.02M -100% $0.00* 0 Aug 3, 2021 Common Stock 2.23M See footnote F1, F3, F4, F5, F6, F11
transaction INAB Series A Preferred Stock Conversion of derivative security $0 -327K -100% $0.00* 0 Aug 3, 2021 Common Stock 359K See footnote F1, F3, F4, F5, F6, F12
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each share of Series A Preferred Stock was convertible at any time at the option of the holder, without payment of additional consideration, into Common Stock, on a 1.0997 for 1 basis, had no expiration date and automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering.
F2 The securities are directly held by Bios Fund II, LP ("Bios Fund II").
F3 Bios Equity Partners II, LP ("Bios Equity II") is the general partner of the following entities: Bios Fund II, Bios Fund II QP, LP ("Bios Fund II QP"), Bios Fund II NT, LP ("Bios Fund II NT") and BIOS Incysus Co-Invest I, LP ("BIOS Incysus"). Bios Equity Partners III, LP ("Bios Equity III") is the general partner of the following entities: Bios Fund III, LP ("Bios Fund III"), Bios Fund III QP, LP ("Bios Fund III QP") and Bios Fund III NT, LP ("Bios Fund III NT"). Bios Capital Management, LP ("Bios Management") and Cavu Management, LP ("Cavu Management") are the general partners of Bios Equity II and Bios Equity III. Bios Advisors GP, LLC ("Bios Advisors") is the general partner of Bios Management. Cavu Advisors LLC ("Cavu Advisors") is the general partner of Cavu Management. Bios Management and Bios Advisors are entities managed and controlled by Aaron G.L. Fletcher. Cavu Management and Cavu Advisors are entities managed and controlled by Leslie W. Kreis, Jr.
F4 Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund II, Bios Fund II QP, Bios Fund II NT, BIOS Incysus, Bios Fund III, Bios Fund III QP and Bios Fund III NT (collectively, the "Bios Equity Entities"). Because of the relationship between Mr. Fletcher, Bios Management, Bios Advisors and the Bios Equity Entities, Mr. Fletcher, Bios Management and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities.
F5 For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.
F6 Mr. Kreis, Cavu Management and Cavu Advisors each share voting and investment control with respect to the shares held by the Bios Equity Entities. Because of the relationship between Mr. Kreis, Cavu Management, Cavu Advisors and the Bios Equity Entities, Mr. Kreis, Cavu Management and Cavu Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities.
F7 The securities are directly held by Bios Fund II QP.
F8 The securities are directly held by Bios Fund II NT.
F9 The securities are directly held by BIOS Incysus.
F10 The securities are directly held by Bios Fund III.
F11 The securities are directly held by Bios Fund III QP.
F12 The securities are directly held by Bios Fund III NT.

Remarks:

This Form 4 is the second of two Forms 4 filed relating to the same event. The Form 4 has been split into two filings because there are more than 10 reporting persons in total, and the SEC's EDGAR filing system limits a single Form 4 to a maximum of 10 reporting person. The first Form 4 was filed by Leslie W. Kreis, Jr. as the designated filer.